Connect with us

Press Release

Babatunde Ojo: Bridging Barrister and Solicitor Roles with Unmatched Legal Precision

Published

6 months ago

on

Kent, UK, 5th August 2025, ZEX PR WIRE, In a legal landscape often defined by specialization, Babatunde Ojo stands out as a rare professional who has mastered both ends of the courtroom. As a barrister and solicitor, Babatunde Ojo brings unmatched legal precision, practical courtroom experience, and strategic advisory capabilities to every case he handles. With over a decade of experience, he continues to elevate standards across the legal profession in the United Kingdom and beyond.

Babatunde Ojo’s journey began with a commitment to excellence. Called to the Bar of England and Wales in 2010 and later admitted to the Roll of Solicitors in 2014, he achieved what few legal practitioners have: seamless fluency across roles traditionally seen as distinct. His dual qualification empowers him to advise clients comprehensively—from pre-trial consultation to courtroom advocacy—without handing off cases midstream. This continuity results in clarity, trust, and outstanding outcomes for those he represents.

At GMSL Legal Services in Kent, Babatunde Ojo has become a cornerstone of the practice. His areas of expertise are expansive and include immigration law, family law, civil and commercial litigation, intellectual property, and public law. Clients seek him out for his ability to cut through complexity and provide clear, actionable legal counsel grounded in the realities of court procedure. He’s not only a fierce advocate in litigation but also a thoughtful strategist when negotiation or mediation is in the client’s best interest.

Legal professionals and clients alike respect Babatunde Ojo for his rigorous attention to detail. “Babatunde is the kind of lawyer who reads everything twice and prepares like every case is going to the Supreme Court,” says a colleague at GMSL. This level of preparation reflects both his respect for the law and his drive to secure the best outcomes possible.

Babatunde Ojo’s legal acumen is backed by a strong academic foundation. He earned his LLB (Hons) from the University of Westminster and completed the Bar Vocational Course at Bristol Law School. He later pursued postgraduate study at the University of Cambridge and is currently undertaking theological studies at the University of Oxford—an intellectual pursuit that underscores his belief in ethical reasoning, social justice, and service.

Beyond the classroom and courtroom, Babatunde Ojo has also contributed to the legal field through academic instruction. He has taught law at various colleges in the UK, helping the next generation of legal minds interpret case law, understand legislation, and approach their responsibilities with integrity. His background as an educator further refines his ability to explain legal concepts in a way that empowers clients and earns the trust of peers.

Babatunde Ojo’s career also includes stints at major London chambers such as Tooks, Westgate, and Furnival, where he completed mini-pupillages and sharpened his skills under some of the UK’s most respected legal minds. These formative experiences exposed him to complex cases involving criminal defence, human rights, and commercial litigation—fields that continue to inform his approach today.

What sets Babatunde Ojo apart isn’t just his legal expertise—it’s his commitment to using the law as a force for good. He has participated in several international legal research initiatives, including projects focused on environmental regulation, sustainable governance, and policy development. His presentations at global conferences reflect a worldview rooted in accountability, justice, and transnational cooperation.

Despite his growing profile, Babatunde Ojo remains grounded in client service. Whether advising on a sensitive family law matter or representing a client in a commercial dispute, he brings the same level of care, clarity, and commitment. He is particularly known for taking on cases others might shy away from—complex immigration appeals, nuanced intellectual property battles, and multi-party civil claims.

“Babatunde doesn’t just practice law—he upholds it,” says a former client who credits him with overturning a deportation order that would have separated a family. “He explained every step, fought every inch, and never treated my case like a file on a desk. He treated it like a human story that mattered.”

Babatunde Ojo’s dedication is also visible in his pro bono work. He volunteers legal guidance to marginalized communities, asylum seekers, and individuals facing barriers to justice. His belief that everyone deserves quality legal representation—regardless of their financial means—has led him to support various nonprofit legal aid initiatives.

As the legal world increasingly shifts toward specialization and siloed knowledge, Babatunde Ojo’s holistic approach reminds the profession of the value of versatility. By bridging the roles of barrister and solicitor, he provides clients with an integrated, consistent experience—one where nothing gets lost in translation between departments or titles. His legal advocacy is strategic yet personal, his advice is technical yet clear, and his presence in the courtroom is both measured and forceful.

Looking ahead, Babatunde Ojo has his eyes set on expanding his influence within the legal sector. He plans to author a series of essays on legal ethics and courtroom strategy, mentor aspiring law students, and develop new frameworks for inclusive access to justice. As the UK continues to navigate challenges in immigration, human rights, and regulatory reform, voices like Babatunde Ojo’s—measured, precise, and grounded in principle—will be essential.

In a world where the law can often feel inaccessible, Babatunde Ojo brings a rare mix of professionalism and approachability. He bridges theory and practice, compassion and strategy, preparation and performance. His career is a testament to what’s possible when legal practice is approached not only with skill but with purpose.

About Babatunde Ojo

 Babatunde Ojo is a British barrister and solicitor based in Kent, UK. He holds an LLB from the University of Westminster, completed the Bar Vocational Course at Bristol Law School, and pursued postgraduate study at the University of Cambridge. A member of The Honourable Society of Gray’s Inn, Babatunde Ojo currently practices law at GMSL Legal Services, specializing in immigration, family law, civil and commercial litigation, public law, and intellectual property.

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Related Topics:
Continue Reading

Press Release

Cloudbet Academy Launches World Cup 2026 Betting Guide: Crypto Strategies and Tournament Insights

Published

6 hours ago

on

January 30, 2026

By

Willemstad, Curaçao – Cloudbet, a leading crypto sportsbook and casino, today announces the release of the World Cup 2026 Betting Guide, a new free course in its Cloudbet Academy platform. Designed specifically for crypto users, this 35-minute open-access guide delivers targeted strategies and practical insights to help bettors navigate the expanded 48-team FIFA World Cup 2026, scheduled for June 11 to July 19, 2026.

The FIFA World Cup consistently ranks as one of the most heavily bet-on sporting events globally, attracting billions in wagers each edition due to its massive scale, international reach, and cultural impact. Industry estimates for recent tournaments place global betting turnover in the tens of billions of dollars, with projections for 2026 suggesting even higher volumes given the tournament’s unprecedented 48-team format and 104 matches.

A Cloudbet spokesperson says, “The 2026 World Cup is a prime moment for crypto bettors. On Cloudbet, with instant deposits and payouts in over 40 cryptocurrencies, you’re in the game within minutes. Stablecoins like USDT let you ride out volatility through the tournament, and low gas fees mean you can move fast when the odds shift. Want to back your country? Your club hero? You can, and with no red tape.”

Hundreds of outrights, player props, team specials, group winners, and other futures markets are already live on Cloudbet. These cover everything from tournament winner and top goalscorer to assists leader and match-specific propositions, giving users immediate access to a broad spectrum of options. For high-stakes bettors, Cloudbet’s Whale Mode—launched just in time for the Super Bowl—enables VIP traders to automate large positions with precision, making it ideal for high-profile tournaments like the World Cup.

The Academy, launched in late 2025, features three core tracks—Crypto Betting Basics, Sports Betting Fundamentals, and Betting Strategies & Analytics—that include interactive quizzes and rewards upon completion. The World Cup 2026 Betting Guide stands apart as the first tournament-specific course. It provides a focused, standalone deep dive that equips crypto users with crypto-optimized approaches to futures positioning, match betting, in-play tactics, and more.

World Cup 2026 Betting Guide: 7 Key Modules

The guide is structured across seven concise modules:

  1. World Cup 2026 basics and tournament format
          Breaks down the expanded 48-team format and how it creates inefficiencies across early group pricing, qualification paths, and futures markets.
     
  2. World Cup outright & futures betting
         Covers early positioning tactics, how to track odds shifts during qualification and the tournament, and how to use stablecoins to manage long-term volatility.
     
  3. How to place World Cup match bets
         Introduces group-stage vs knockout-stage dynamics and teaches contextual analysis beyond surface-level rankings.
     
  4. World Cup props, specials & group-based markets
         Focuses on Golden Boot, assist leaders, group winners, and other specials—plus how to adjust for neutral-venue effects.
     
  5. World Cup vs club football: What’s the difference?
         Explains key differences in tempo, tactics, pressure, and bankroll management between international and club football.
     
  6. World Cup live betting strategies
         Explores how to spot momentum swings in real time and use on-chain sentiment indicators to find edge in fast-moving markets.
     
  7. Advanced World Cup betting strategies & common mistakes (Advanced)
         Covers sharp techniques like futures hedging, accumulator timing, and how to avoid common pitfalls like public sentiment chasing and overconfidence.

World Cup 2026 Qualification Snapshot

As of January 2026, 42 nations have qualified, including co-hosts USA, Canada, and Mexico, plus major teams from every confederation such as Spain, England, France, Argentina, Brazil, Japan, and Morocco. The December 2025 draw has set the groups, and six final spots will be decided in March 2026 through UEFA play-offs and the inter-confederation tournament in Mexico.

The Academy’s ‘World Cup Outright & Futures Betting‘ module covers more on this, including strategies for betting on group qualification, interpreting odds movements during play-offs, and positioning early in long-term markets amid uncertainty.

A Cloudbet spokesperson noted, “With groups locked in and just a few spots left, now’s the window where early odds still reflect uncertainty. This is when sharp bettors get in—before pricing tightens after March and public money floods the markets in June.”

Current World Cup 2026 Outright Odds on Cloudbet (as of January 2026)

●     Spain: 5.55 odds

●     England: 6.64 odds

●     France: 8.99 odds

●     Brazil: 9.11 odds

●     Argentina: 9.13 odds

For the latest odds, visit Cloudbet.com.

Access the World Cup 2026 Betting Guide now at cloudbet.com/en/academy/world-cup-2026-betting-guide

About Cloudbet

Founded in 2013, Cloudbet is the world’s longest-running crypto sportsbook and casino. Players can bet with over 40 cryptocurrencies across thousands of sports markets and a full portfolio of casino games, including slots, live dealers, and provably fair crypto titles.

Cloudbet has processed millions of bets securely, offering sharp odds, high limits, instant crypto payouts, and 24/7 customer support.

In 2024, Cloudbet introduced a welcome offer and loyalty program built for serious players—real cash rewards, daily cash drops, and 10% rakeback with no wagering requirements.

From Premier League and NFL props to esports, tennis, and basketball, Cloudbet delivers the sharp action crypto bettors expect.

Find us at Cloudbet.com, on Instagram @cloudbetofficial, and Twitter/X @Cloudbet.

 

Media Contact

Irene@media.cloudbet.com  

 

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream Obtained China NDA Approval, Becoming The First and Only Targeted Drug for Vitiligo in China

Published

6 hours ago

on

January 30, 2026

By

SHENZHEN, CHINA – China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by the Group on 22 April 2025 for details) received approval from the National Medical Products Administration of China (NMPA) on 30 January 2026 for the New Drug Application (NDA) of ruxolitinib phosphate cream (the “Product”) for the treatment of non-segmental vitiligo with facial involvement in children aged 12 years and older and adult patients. It is the first and only targeted drug approved in China for vitiligo, addressing a significant unmet clinical need.

Ruxolitinib phosphate cream is the first and only drug approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for repigmentation in nonsegmental vitiligo[1,2]. Prior to receiving formal NDA approval, the Group benefited from the “Early and Pilot Implementation” policy granted to the Hainan Free Trade Port and Lecheng Pilot Zone (“Lecheng Pilot Zone”), the “Hong Kong and Macau Medicine and Equipment Connect” policy, and the clinically urgently needed imported drug policies of the Beijing and Tianjin Free Trade Zones, and had already initiated the pilot application of ruxolitinib phosphate cream. Currently, Boao Super Hospital has prescribed ruxolitinib phosphate cream to over 7,000 patients with non-segmental vitiligo, and more than twenty hospitals in Guangzhou, Shenzhen, Dongguan, Foshan, Zhongshan, Zhuhai, Jiangmen, Huizhou, Beijing and Tianjin have provided prescription services for the Product, demonstrating its clinical potential.

The product has shown positive results in both overseas clinical studies and the real-world study in China: in two identical Phase III double-blind, randomized, placebo-controlled studies (TRuE-V1 and TRuE-V2) conducted overseas, the proportion of patients achieving the primary efficacy endpoint of at least 75% improvement in the Facial Vitiligo Area Score Index (F-VASI 75) after 24 weeks of treatment with ruxolitinib phosphate cream was 29.9% in both studies, significantly higher than the 7.5% and 12.9% in the placebo groups, respectively. Continued use up to 52 weeks showed sustained repigmentation[3]. In accordance with the relevant regulations of the Lecheng Pilot Zone’s real-world data application pilot project, ruxolitinib phosphate cream underwent real-world study in China, demonstrating positive efficacy consistent with the results of overseas pivotal clinical studies. All secondary efficacy endpoints in both domestic and overseas clinical studies showed a benefit trend consistent with the primary efficacy endpoint, and the treatment effect for vitiligo continued to improve with prolonged treatment. Furthermore, according to safety monitoring data from the Lecheng Pilot Zone, no new safety event was identified, no adverse event (AE) leading to discontinuation or withdrawal of treatment occurred, and no study drug-related serious adverse event (SAE) occurred.

This approval in vitiligo brings new hope for treatment to over 10 million vitiligo patients in China, addressing urgent clinical needs. At the same time, it will add to Dermavon’s product portfolio in the field of skin treatment, potentially synergizing with Dermavon’s commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized exclusive drug Hirudoid (mucopolysaccharide polysulfate cream), and a series of innovative drugs under development and dermatological skin care products, in terms of expert network and market resources, thereby potentially enhancing Dermavon’s position in the field of skin health.

Furthermore, the Phase III clinical trial in China of ruxolitinib phosphate cream for the treatment of mild to moderate atopic dermatitis (AD) has achieved positive results. Currently, the Group is actively advancing the NDA for ruxolitinib phosphate cream for the treatment of AD in China, which, if approved, will provide a new treatment option for a broader patient population with AD in China.

About Vitiligo

Vitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. It is estimated that there are approximately 10.3 million vitiligo patients in China and non-segmental vitiligo patients account for approximately 8.2 million[4]. Existing therapies, such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs), have clinical limitations, with adverse reactions or limited efficacy with long-term use. The NDA approval of ruxolitinib phosphate cream successfully fills the gap in targeted drug treatment for vitiligo and is of great landmark significance. 

More About Ruxolitinib Phosphate Cream

Ruxolitinib phosphate cream (Opzelura®), a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte, is approved for the topical treatment of nonsegmental vitiligo in adult and patients aged 12 years and older, and for the short-term and non-continuous chronic treatment of mild to moderate AD in patients aged 2 years and older without immunodeficiency in the U.S. In Europe, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.

The Group, through a subsidiary of Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream on 2 December 2022, obtaining an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights for the Product outside Mainland China to the Group (excluding Dermavon and its subsidiary).

Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream, marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte.

 

About CMS

 

CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.

 

CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.

 

CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development  of the Group.

 

Reference:

  1. The U.S. FDA approval information can be found on the Incyte official website, as follows:

https://investor.incyte.com/news-releases/news-release-details/incyte-announces-us-fda-approval-opzeluratm-ruxolitinib-cream

  1. The EMA approval information can be found on the Incyte official website, as follows:

https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurar

  1. The clinical studies information can be found on the Opzelura® official website, as follows:

https://www.opzelura.com/opzelura-prescribing-information

  1. China Insights Consultancy’s industrial report

 

CMS Disclaimer and Forward-Looking Statements

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

 

Media Contact

Brand: China Medical System Holdings Ltd.

Contact: CMS Investor Relations

Email: ir@cms.net.cn

Website: https://web.cms.net.cn/en/home/

 

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Gabriel Malkin Florida Completes 120-Mile Camino Walk with Focus, Patience, and Preparation

Published

11 hours ago

on

January 30, 2026

By

Florida, US, 30th January 2026, ZEX PR WIRE, Most students don’t spend the start of summer walking across northern Spain. Gabriel Malkin did. In June 2025, the Florida high school graduate completed a 120-mile stretch of the Camino de Santiago, one of the world’s oldest pilgrimage routes. It wasn’t a last-minute idea. It was a goal he had planned for, trained for, and quietly worked toward for months.

This wasn’t about adventure or social media. For Gabriel, it was about setting a physical goal and showing up for it every day.

“I didn’t want to wing it,” he said. “It was important to take it seriously.”

Gabriel’s prep started long before his flight to Europe. He built up mileage slowly, starting with short daily walks in South Florida. As the months went on, he added distance, tested gear, and paid attention to recovery. Blisters, sore muscles, and weather were all part of the process. So was building patience.

“The Camino isn’t just hard because it’s long,” Gabriel said. “It’s hard because you have to get up and do it again every day. Even when you’re tired. Even when nothing hurts and you feel fine—you still have to walk.”

The daily rhythm became its own challenge. Mornings often started before sunrise, with quiet stretches of trail through farmland, hills, and towns. Gabriel carried a small pack with essentials. Water, snacks, extra socks. No Wi-Fi. No schedule beyond the day’s distance. Just a clear goal and a few hours of steady effort.

That focus and consistency mirrors how Gabriel approaches most things. Whether he’s in class, on the tennis court, or working on saxophone tone, he tends to favor structure and repetition over shortcuts. It’s not about perfection. It’s about showing up, improving slowly, and staying with it.

“I’ve never been the fastest or the strongest at anything,” he said. “But I like knowing I’m getting better, even if it’s slow.”

Gabriel grew up in South Florida and attended Virginia Shuman Young Elementary, Pine Crest in Fort Lauderdale, and NSU University School in Davie. He played tennis, baseball, and football through different stages of school. He also spent time hiking local trails and practicing saxophone, two interests he says helped him train for the Camino more than people might expect.

“Hiking helped with endurance, obviously,” he said. “But playing music teaches you a lot about repetition and listening to your body. You learn when to push and when to pause.”

For Gabriel, the Camino wasn’t a performance or a competition. It was a quiet personal test. He kept notes during the walk, not for a blog, but to track how each day felt. When he crossed the finish line in Santiago, there was no big moment. Just a quiet sense of completion.

Now back home, Gabriel hasn’t stopped walking. He’s back to local trails, early mornings, and training logs. He’s also thinking about what comes next—college, travel, more endurance goals—but isn’t rushing anything.

“There’s no rush,” he said. “The Camino reminded me that showing up every day matters more than trying to get somewhere fast.”

Gabriel Malkin Florida continues to build habits rooted in preparation, consistency, and follow-through. Whether through athletics, academics, or music, his focus remains steady: stay curious, stay active, and finish what you start.

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST

Like Us
Follow Us
Subscribe Us
Follow Us